We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Highlights of Translational and Molecular Research Presented at the European Society for Medical Oncology Annual Meeting 2023.
- Authors
Pouyiourou, Maria; Reitnauer, Lea Elisabeth; Ballhausen, Alexej; Alig, Annabel Helga Sophie; Bleckmann, Annalen; Westphalen, Christoph Benedikt; Kloft, Maximilian
- Abstract
This document provides information on highlights from the European Society for Medical Oncology Annual Meeting 2023. One highlight is the CUPISCO trial, which found that comprehensive genomic profiling can improve treatment decisions and survival outcomes for cancer of unknown primary. Another trial, the CUP-ONE trial, showed that gene expression profiling is more accurate than immunohistochemistry in certain subgroups of patients. The ORIGIN-PanCA○R trial demonstrated that site-specific treatment guided by a gene expression assay improved progression-free survival in newly diagnosed CUP patients. The article also mentions the development of RAS inhibitors, specifically RMC-6236, which shows promise in treating certain types of cancer. Additionally, the use of Erdafitinib, an FGFR inhibitor, showed promise in treating pancreatic cancer. Both studies emphasize the need for further research to fully understand the safety and efficacy of these treatments.
- Subjects
MEDICAL societies; CANCER of unknown primary origin; TRANSLATIONAL research; FIBROBLAST growth factor receptors; GALLBLADDER cancer
- Publication
Oncology Research & Treatment, 2024, Vol 47, Issue 4, p149
- ISSN
2296-5270
- Publication type
Article
- DOI
10.1159/000537940